Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis

Table 2 Baseline characteristics of the study patients (unknown previous virologic response patients, n = 57)

	All patients (n = 1057)				TN (n = 319)			R (n = 298)			PR (n = 123)			NR (n = 260)
	All (n = 1057)	BOC (n = 405)	TVR (n = 652)	P value	BOC (n = 130)	TVR (n = 189)	P value	BOC (n = 77)	TVR (n = 221)	P value	BOC (n = 55)	TVR (n = 68)	P value	BOC (n = 119)	TVR (n = 141)	P value
Age (yr), mean ± SD	54 ± 8	54 ± 9	53 ± 8		52 ± 10	53 ± 9		54.6 ± 8	53 ± 8		54.6 ± 8	53 ± 8		54 ± 9	54 ± 7
Male sex	724 (69)	264 (65)	460 (71)	NS	85 (65)	124 (66)	NS	46 (60)	157 (71)	NS	35 (64)	55 (81)	0.03	85 (71)	101 (72)	NS
HCV genotype 1 subtype
1a	239 (26)	102 (28)	137 (24)	NS	32 (27)	47 (29)	NS	18 (25)	38 (20)	NS	15 (31)	13 (23)	NS	34 (32)	31 (24)	NS
1b	692 (74)	263 (72)	429 (76)		85 (73)	116 (71)		54 (75)	151 (80)		34 (69)	44 (77)		72 (68)	99 (76)
IL28b genotype
CC	157 (20)	55 (18)	102 (20)	NS	27 (26)	35 (23)	NS	8 (16)	46 (29)	NS	5 (13)	5 (9)	NS	9 (10)	9 (8)	NS
CT	510 (63)	191 (64)	319 (63)		57 (54)	94 (61)		36 (74)	97 (61)		24 (63)	38 (72)		61 (70)	77 (68)
TT	138 (17)	54 (18)	84 (17)		21 (20)	24 (16)		5 (10)	16 (10)		9 (24)	10 (19)		17 (20)	27 (24)
Stage of fibrosis
F0F1	81 (8)	46 (12)	35 (6)	0.002	19 (15)	4 (2)	0	11 (15)	27 (14)	NS	8 (16)	2 (3)	0.03	3 (3)	1 (1)	NS
F2	138 (14)	42 (11)	96 (16)		17 (14)	28 (16)		7 (10)	31 (16)		3 (6)	9 (14)		14 (12)	20 (16)
F3	204 (21)	76 (20)	128 (22)		27 (22)	34 (20)		21 (29)	41 (21)		7 (14)	15 (24)		16 (14)	32 (25)
F4	545 (56)	217 (57)	328 (56)		60 (49)	105 (62)		34 (46)	98 (49)		32 (64)	37 (59)		80 (71)	72 (58)
Hb (g/dL)	15 ± 1	15 ± 1.5	15.1 ± 1.5	NS	15 ± 1.6	14.8 ± 1.5	NS	15 ± 1.6	15.3 ± 1.3	NS	14.9 ± 1.5	15.2 ± 1.5	NS	15.2 ± 1.5	15.3 ± 1.6	NS
PMN (mL)	3228 ± 1305	3241.4 ± 1329.6	3220.4 ± 1290.3	NS	3317.8 ± 1250.4	3155.1 ± 1276.1	NS	3499 ± 1405	3366 ± 1392	NS	3002 ± 1364.5	3168 ± 1182.5	NS	3156 ± 1385.5	3176.0 ± 1208.1	NS
Platelets (%)	161358 ± 66199	162194.7 ± 65144.4	160841.2 ± 66889.7	NS	169727.3 ± 68082	159038.1 ± 72104.9	NS	172671 ± 69822	178393 ± 66412	NS	156907 ± 57085	147308 ± 61828	NS	154046 ± 62558	144128.6 ± 55066	NS
Prothrombin (%)	94 ± 14	94.7 ± 12.6	92.7 ± 14.8	NS	93.7 ± 11	95.6 ± 15.3	NS	94.2 ± 13.0	90 ± 15	NS	95.8 ± 16.0	93.4 ± 11.0	NS	95.6 ± 0.7	92.6 ± 15.5	NS
ALT (IU/mL)	89 ± 65	88.9 ± 70.1	89.8 ± 61.6	NS	80.6 ± 55	92.4 ± 62.0	NS	80 ± 64	76.0 ± 51.2	NS	90 ± 53	87 ± 46	NS	93.6 ± 48.8	106.3 ± 77.0	NS
GGT (IU/mL)	107 ± 103	115.3 ± 106.1	101.8 ± 101.3	0.050	90.6 ± 86.5	107.0 ± 133.8	NS	110 ± 144	81.2 ± 70.0	NS	116.8 ± 79.0	113.0 ± 87.5	NS	143.1 ± 107.0	117.7 ± 93.0	0.040
Alkaline phosphatase (mL)	95 ± 46	93.6 ± 40.8	95.2 ± 49.6	NS	88.4 ± 31	99 ± 57	NS	89.4 ± 30.0	89.3 ± 43.0	NS	99.6 ± 50.6	101.8 ± 48.1	NS	96.7 ± 46.6	95.1 ± 49.1	NS
Albumin (g/L)	4.0 ± 0.5	4.18 ± 0.428	4.25 ± 0.52	0.040	4.2 ± 0.5	4.2 ± 0.4	NS	4.2 ± 0.4	4.4 ± 0.4	0.030	4.1 ± 0.4	4.3 ± 0.5	0.020	4.2 ± 0.4	4.0 ± 0.6	NS
Creatinine (mg/dL)	0.8 ± 0.2	0.79 ± 0.16	0.81 ± 0.2	NS	0.8 ± 0.2	0.8 ± 0.1	NS	0.8 ± 0.2	0.8 ± 0.2	NS	0.8 ± 0.2	0.8 ± 0.2	NS	0.7 ± 0.2	0.8 ± 0.22	NS
HCV viral load (IU/mL)	3.3 × 106± 6 × 106	3.5 × 106± 5.9 × 106	3.2 × 106± 5.9 × 106	NS	3.5 × 106± 6.2 × 106	3.8 × 106± 8.9 × 106	NS	2.8 × 106± 3.8 × 106	3 × 106± 4.1 × 106	NS	4.1 × 106± 9.5 × 106	2.3 × 106± 2.6 × 106	NS	3.3 × 106± 4.7 × 106	3 × 106± 4 × 106	NS

n (%) and χ² tests summarise the categorical variables; mean ± SD and Student’s t-test or Mann-Whitney U test summarise the continuous variables. NS: Not significant; BOC: Boceprevir; TVR: Telaprevir; TN: Treatment-naïve; R: Relapsers; PR: Partial responders; NR: Null responders.